F8 and hemophilia: Our results suggest TGT parameters measured using the ST Genesia® platform may represent a suitable tool to monitor the hemostatic status of patients requiring a closer follow-up and a tailored therapeutic adjustment, overcoming the limitations of FVIII activity laboratory tests in clinical practice, and its application may be extended to other types of hemophilia or bleeding disorders.